Egs molecules that specifically downregulae bcl-xl experession
OwnerCy Steininventor
Life of this patent
Estimating the term…
Loading patent…
OwnerCy Steininventor
Estimating the term…
This invention provides a nuclease-resistant external guide sequence (EGS) oligonucleotide selected from the group consisting of Inno-1405, Inno-1407 and Bcl-xL1 whose sequences are set forth in Table 1. This invention also provides a method of inducing specific intracellular mRNA cleavage through activation of RNase P comprising contacting a cell with a complex comprising an EGS oligonucleotide and a carrier. This invention provides methods of downregulating PKC-α protein expression and PKC-α mRNA expression comprising contacting a cell with a complex comprising an EGS oligonucleotide and a carrier. This invention provides methods of downregulating bcl-xL protein expression and bcl-xL mRNA expression comprising contacting a cell with a complex comprising an EGS oligonucleotide and a carrier.
A nuclease-resistant external guide sequence (EGS) oligonucleotide selected from the group consisting of Inno-1405, Inno-1407 and Bcl-xL1 whose sequences are set forth in Table 1.
A method of inducing specific intracellular mRNA cleavage through activation of RNase P comprising contacting a cell with a complex comprising an EGS oligonucleotide and a carrier.
A method of downregulating PKC-α protein expression comprising contacting a cell with a complex comprising an EGS oligonucleotide and a carrier.
The method of claim wherein the cationic lipid is Lipofectin or LipofectACE.
A method of downregulating bcl-xL protein expression comprising contacting a cell with a complex comprising an EGS oligonucleotide and a carrier.
A method of downregulating PKC-α mRNA expression comprising contacting a cell with a complex comprising an EGS oligonucleotide and a carrier.
A method of downregulating bcl-xL mRNA expression comprising contacting a cell with a complex comprising an EGS oligonucleotide and a carrier.
Dependencies are inferred from the claim text.